Literature DB >> 30706176

Race influences survival in glioblastoma patients with KPS ≥ 80 and associates with genetic markers of retinoic acid metabolism.

Meijing Wu1, Jason Miska1, Ting Xiao1, Peng Zhang1, J Robert Kane1, Irina V Balyasnikova1, James P Chandler1,2, Craig M Horbinski1,2, Maciej S Lesniak3,4.   

Abstract

PURPOSE: To study whether the clinical outcome and molecular biology of gliomas in African-American patients fundamentally differ from those occurring in Whites.
METHODS: The clinical information and molecular profiles (including gene expression array, non-silent somatic mutation, DNA methylation and protein expression) were downloaded from The Cancer genome atlas (TCGA). Electronic medical records were abstracted from Northwestern Medicine Enterprise Data Warehouse (NMEDW) for analysis as well. Grade II-IV Glioma patients were all included.
RESULTS: 931 Whites and 64 African-American glioma patients from TCGA were analyzed. African-American with Karnofsky performance score (KPS) ≥ 80 have significantly lower risk of death than similar white Grade IV Glioblastoma (GBM) patients [HR (95% CI) = 0.47 (0.23, 0.98), P = 0.0444, C-index = 0.68]. Therefore, we further compared gene expression profiles between African-American GBM patients and Whites with KPS ≥ 80. Extrapolation of genes significantly associated with increased African-American patient survival revealed a set of 13 genes with a possible role in this association, including elevated expression of genes previously identified as increased in African-American breast and colon cancer patients (e.g. CRYBB2). Furthermore, gene set enrichment analysis revealed retinoic acid (RA) metabolism as a pathway significantly upregulated in African-American GBM patients who survive longer than Whites (Z-score = - 2.10, Adjusted P-value = 0.0449).
CONCLUSIONS: African Americans have prolonged survival with glioma which is influenced only by initial KPS score. Genes previously associated with both racial disparities in cancer and pathways associated with RA metabolism may play an important role in glioma etiology. In the future exploration of these genes and pathways may inform novel therapies for this incurable disease.

Entities:  

Keywords:  African Americans; Glioma; Karnofsky performance score; Retinoic acid metabolism; Whites

Mesh:

Substances:

Year:  2019        PMID: 30706176      PMCID: PMC6450757          DOI: 10.1007/s11060-019-03110-5

Source DB:  PubMed          Journal:  J Neurooncol        ISSN: 0167-594X            Impact factor:   4.130


  29 in total

1.  Racial/ethnic differences in survival among elderly patients with a primary glioblastoma.

Authors:  Jill S Barnholtz-Sloan; John L Maldonado; Vonetta L Williams; William T Curry; Elizabeth A Rodkey; Frederick G Barker; Andrew E Sloan
Journal:  J Neurooncol       Date:  2007-05-26       Impact factor: 4.130

2.  The human tumor antigen PRAME is a dominant repressor of retinoic acid receptor signaling.

Authors:  Mirjam T Epping; Liming Wang; Michael J Edel; Leone Carlée; Maria Hernandez; René Bernards
Journal:  Cell       Date:  2005-09-23       Impact factor: 41.582

3.  Trends in brain cancer incidence and survival in the United States: Surveillance, Epidemiology, and End Results Program, 1973 to 2001.

Authors:  Sundeep Deorah; Charles F Lynch; Zita A Sibenaller; Timothy C Ryken
Journal:  Neurosurg Focus       Date:  2006-04-15       Impact factor: 4.047

4.  Clinical implications of PRAME gene expression in childhood acute myeloid leukemia.

Authors:  Daniel Steinbach; Johann Hermann; Susanne Viehmann; Felix Zintl; Bernd Gruhn
Journal:  Cancer Genet Cytogenet       Date:  2002-03

5.  Racial differences in the incidence of gliomas: a retrospective study from Memphis, Tennessee.

Authors:  J T Robertson; B C Gunter; G W Somes
Journal:  Br J Neurosurg       Date:  2002-12       Impact factor: 1.596

6.  The tumor-associated antigen PRAME is universally expressed in high-stage neuroblastoma and associated with poor outcome.

Authors:  André Oberthuer; Barbara Hero; Rüdiger Spitz; Frank Berthold; Matthias Fischer
Journal:  Clin Cancer Res       Date:  2004-07-01       Impact factor: 12.531

7.  Racial differences in survival after diagnosis with primary malignant brain tumor.

Authors:  Jill S Barnholtz-Sloan; Andrew E Sloan; Ann G Schwartz
Journal:  Cancer       Date:  2003-08-01       Impact factor: 6.860

Review 8.  Epidemiology of primary brain tumors: current concepts and review of the literature.

Authors:  Margaret Wrensch; Yuriko Minn; Terri Chew; Melissa Bondy; Mitchel S Berger
Journal:  Neuro Oncol       Date:  2002-10       Impact factor: 12.300

9.  Participation in cancer clinical trials: race-, sex-, and age-based disparities.

Authors:  Vivek H Murthy; Harlan M Krumholz; Cary P Gross
Journal:  JAMA       Date:  2004-06-09       Impact factor: 56.272

10.  Relative survival rates and patterns of diagnosis analyzed by time period for individuals with primary malignant brain tumor, 1973-1997.

Authors:  Jill S Barnholtz-Sloan; Andrew E Sloan; Ann G Schwartz
Journal:  J Neurosurg       Date:  2003-09       Impact factor: 5.115

View more
  6 in total

1.  Racial disparities in pediatric malignant glioma management: current state of affairs in the United States.

Authors:  Victor M Lu; Toba N Niazi
Journal:  J Neurooncol       Date:  2022-09-08       Impact factor: 4.506

2.  African Americans and European Americans exhibit distinct gene expression patterns across tissues and tumors associated with immunologic functions and environmental exposures.

Authors:  Urminder Singh; Kyle M Hernandez; Bruce J Aronow; Eve Syrkin Wurtele
Journal:  Sci Rep       Date:  2021-05-10       Impact factor: 4.379

3.  A functional role for the cancer disparity-linked genes, CRYβB2 and CRYβB2P1, in the promotion of breast cancer.

Authors:  Maya A Barrow; Megan E Martin; Alisha Coffey; Portia L Andrews; Gieira S Jones; Denise K Reaves; Joel S Parker; Melissa A Troester; Jodie M Fleming
Journal:  Breast Cancer Res       Date:  2019-09-11       Impact factor: 6.466

4.  Inhibition of human glioblastoma cell invasion involves PION@E6 mediated autophagy process.

Authors:  Zhongyu Ren; Jing Liang; Peng Zhang; Jianjiao Chen; Jian Wen
Journal:  Cancer Manag Res       Date:  2019-03-29       Impact factor: 3.989

5.  Disparities in Reported Testing for 1p/19q Codeletion in Oligodendroglioma and Oligoastrocytoma Patients: An Analysis of the National Cancer Database.

Authors:  Jad Zreik; Panagiotis Kerezoudis; Mohammed Ali Alvi; Yagiz U Yolcu; Sani H Kizilbash
Journal:  Front Oncol       Date:  2021-11-09       Impact factor: 6.244

6.  Physiological and pathological functions of βB2-crystallins in multiple organs: a systematic review.

Authors:  Meihui Li; Shengnan Liu; Wei Huang; Junjie Zhang
Journal:  Aging (Albany NY)       Date:  2021-06-11       Impact factor: 5.682

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.